ImmunityBio (IBRX) Current Leases (2016 - 2026)

ImmunityBio (IBRX) has 11 years of Current Leases data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Current Leases rose 2.23% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 2.23% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, up 0.92% from the prior year.
• Current Leases for Q1 2026 stood at $7.6 million, up from $7.5 million in the prior quarter.
• Over the last five years, Current Leases for IBRX reached as high as $7.6 million in Q1 2026 and fell as low as $1.4 million in Q3 2022.
• Historically, Current Leases has averaged $5.4 million across 5 years, with a median of $6.1 million in 2024.
• Across the five-year window, Current Leases tumbled 55.57% in 2022 and jumped 326.21% in 2023, its largest moves.
• Year by year, Current Leases stood at $2.6 million in 2022, then jumped by 97.89% to $5.2 million in 2023, then soared by 42.37% to $7.5 million in 2024, then increased by 0.92% to $7.5 million in 2025, then climbed by 1.21% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $7.6 million in Q1 2026, $7.5 million in Q4 2025, and $7.3 million in Q3 2025.